Precigen, Inc.
MUC16 specific chimeric antigen receptors and uses thereof

Last updated:

Abstract:

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

Status:
Grant
Type:

Utility

Filling date:

4 Jun 2019

Issue date:

3 May 2022